Citation Impact
Citing Papers
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
2007
Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
2013
Natural products: An evolving role in future drug discovery
2011 Standout
Marine natural products
1990 Standout
Drug development from marine natural products
2008 Standout
Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer
2007
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer
2011
Natural compounds for cancer treatment and prevention
2009 Standout
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
2010 Standout
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Marine natural products
2015 Standout
Trabectedin (Et-743): Evaluation of Its Use In Advanced Soft-Tissue Sarcoma
2007
Works of A. Poveda being referenced
Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results
2006
Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study.
2010
A phase II study of oral gimatecan (ST1481) in women with progressing or recurring advanced epithelial ovarian, fallopian tube and peritoneal cancers
2006